Skip to main content

Table 3 Incidence of adverse events associated with traditional NSAIDs or iCOX2 compared to placebo in patients with axSpA: meta-analysis of randomized clinical trials

From: Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis

  TRADITIONAL NSAIDs
N=1289
iCOX2
N=669
Adverse events 35.6% vs 36.4% (PbO)
RR=1.08 (0.93 to 1.25)
54.6% vs 46.4% (PbO)
RR=1.22 (0.93 to 1.62)
Severe adverse events 1% vs 0.6% (PbO)
RR=1.71 (0.37 to 8.01)
0.6% vs 0.6% (PbO)
RR=0.96 (0.17 to 5.53)
Gastrointestinal adverse events 18% vs 9.5% (PbO)
RR=1.92 (1.41 to 2.61)
17.7% vs 7.5% (PbO)
RR=2.55 (1.92 to 4.95)
Discontinuation due to adverse events 5% vs 5.5% (PbO)
RR=0.76 (0.48 to 1.22)
4.6% vs 3.4% (PbO)
RR=2.14 (0.36 to 12.56)
  1. NSAIDs nonsteroidal anti-inflammatory drugs, iCOX2 selective cyclooxygenase 2 inhibitors, PbO placebo, RR relative risk